ASMB Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of 39.21%. Assembly Biosciences, Inc.'s return on equity of -67.09% beat Gilead Sciences, Inc.'s return on equity of 41.48%.

Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 40.4%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $132.38 which suggests that it could grow by 7.85%. Given that Assembly Biosciences, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than Gilead Sciences, Inc..

Assembly Biosciences, Inc. has a beta of 1.143, which suggesting that the stock is 14.321% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.334, suggesting its less volatile than the S&P 500 by 66.568%.

Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.58% to investors and pays a quarterly dividend of $0.79 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.

Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. Assembly Biosciences, Inc.'s net income of -$9.2M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 19.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.87x versus 5.31x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of -255.85%. Assembly Biosciences, Inc.'s return on equity of -67.09% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 40.4%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.93%. Given that Assembly Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Assembly Biosciences, Inc. has a beta of 1.143, which suggesting that the stock is 14.321% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Assembly Biosciences, Inc.'s net income of -$9.2M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.87x versus 10.96x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of --. Assembly Biosciences, Inc.'s return on equity of -67.09% beat Palatin Technologies's return on equity of --.

Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 40.4%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Assembly Biosciences, Inc., analysts believe Palatin Technologies is more attractive than Assembly Biosciences, Inc..

Assembly Biosciences, Inc. has a beta of 1.143, which suggesting that the stock is 14.321% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.

Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are larger than Palatin Technologies quarterly revenues of --. Assembly Biosciences, Inc.'s net income of -$9.2M is higher than Palatin Technologies's net income of --. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.87x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Supernus Pharmaceuticals, Inc. has a net margin of -85.24% compared to Assembly Biosciences, Inc.'s net margin of -23.49%. Assembly Biosciences, Inc.'s return on equity of -67.09% beat Supernus Pharmaceuticals, Inc.'s return on equity of -1.84%.

Assembly Biosciences, Inc. has a consensus price target of $47.75, signalling upside risk potential of 40.4%. On the other hand Supernus Pharmaceuticals, Inc. has an analysts' consensus of $61.33 which suggests that it could grow by 23.41%. Given that Assembly Biosciences, Inc. has higher upside potential than Supernus Pharmaceuticals, Inc., analysts believe Assembly Biosciences, Inc. is more attractive than Supernus Pharmaceuticals, Inc..

Assembly Biosciences, Inc. has a beta of 1.143, which suggesting that the stock is 14.321% more volatile than S&P 500. In comparison Supernus Pharmaceuticals, Inc. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.701%.

Assembly Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Supernus Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assembly Biosciences, Inc. pays -- of its earnings as a dividend. Supernus Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Assembly Biosciences, Inc. quarterly revenues are $10.8M, which are smaller than Supernus Pharmaceuticals, Inc. quarterly revenues of $192.1M. Assembly Biosciences, Inc.'s net income of -$9.2M is higher than Supernus Pharmaceuticals, Inc.'s net income of -$45.1M. Notably, Assembly Biosciences, Inc.'s price-to-earnings ratio is -- while Supernus Pharmaceuticals, Inc.'s PE ratio is 41.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assembly Biosciences, Inc. is 7.87x versus 4.11x for Supernus Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.